Intermune Inc
General
Total Cases31
Active Cases--
Patents53
Ratings
Experience
Grade
Trend
DCT
L4
A
PTAB
L5
E
CAFC
L4
D
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 02/03/23 | Joint Letter to The Clerk of Court, regarding the discarding of trial exhibits (D.I. 438 ). (Clark, Cameron) Modified on 2/3/2023 (nms). (Entered: 02/03/2023) | |
| 02/03/23 | Remark: The bench trial exhibits (see D.I. 362 Exhibit List) have been destroyed per the authority at D.I. 439 . (nms) (Entered: 02/03/2023) | |
| 01/30/23 | Letter to Counsel, from the Clerk of Court, regarding return of trial exhibits -(see D.I. 362 Exhibit List). (nms) (Entered: 01/30/2023) | |
| 01/30/23 | MANDATE of USCA as to 397 Notice of Appeal (Federal Circuit), filed by Genentech, Inc., InterMune, Inc.. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 01/30/2023) | |
| 10/06/22 | ORAL ORDER: The redactions at D.I. 389, 390, 391, and 393 as supported by the declarations at D.I. 403 and D.I. 404 are APPROVED. Ordered by Judge Richard G. Andrews on 10/6/2022. (nms) (Entered: 10/06/2022) | |
| 06/16/22 | MANDATE of USCA as to 433 Notice of Cross Appeal, filed by Lek Pharmaceuticals D.D., Sandoz Inc.. USCA Decision: The motion is granted. Appeal No. 2022-1714 is dismissed. The revised official caption for the remaining appeal, Appeal No. 2022-1595, is reflected above. (2) Each side shall bear its own costs in Appeal No. 2022-1714. (3) The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal No. 2022 1595. (4) Genentech, Inc. and InterMune, Inc.s reply brief in Appeal No. 2022-1595 is due no later than July 5, 2022. (nms) (Entered: 06/16/2022) | |
| 04/22/22 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 433 Notice of Cross Appeal, filed by Lek Pharmaceuticals D.D., Sandoz Inc.. USCA Case Number 2022-1714. (nms) (Entered: 04/22/2022) | |
| 04/21/22 | NOTICE OF CROSS APPEAL to the Federal Circuit of 396 Judgment . Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) (Entered: 04/21/2022) | |
| 04/21/22 | APPEAL - Credit Card Payment of $505.00 received re 433 Notice of Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. ( Filing fee $505, receipt number ADEDC-3856953.) (Brauerman, Stephen) (Entered: 04/21/2022) | |
| 04/21/22 | Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re 433 Notice of Cross Appeal. (nmg) (Entered: 04/21/2022) |